A Phase 3b Randomized, Double-blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Gefapixant in Women With Chronic Cough and Stress Urinary Incontinence
A Phase 3b Randomized, Double-blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Gefapixant in Women With Chronic Cough and Stress Urinary Incontinence
The purpose of this study is to evaluate the efficacy and safety of gefapixant, in improving symptoms of cough-induced stress urinary incontinence (SUI) in adult female participants with refractory or unexplained chronic cough. The primary hypothesis is that gefapixant is superior to placebo in reducing the frequency of cough-induced SUI episodes over 12 weeks.
Inclusion Criteria:
Exclusion Criteria:
Williamsburg, Virginia 23188, United States
Medellín, Antioquia 050036, Colombia
Marburg, Hesse 35037, Germany
Neu-Isenburg, Hesse 63263, Germany
Guatemala City, 01010, Guatemala
Guatemala City, 01010, Guatemala
Belgorod, Belgorod Oblast 308007, Russia
Kemerovo, Kemerovo Oblast 650000, Russia
Moscow, Moscow 115419, Russia
Novosibirsk, Novosibirsk Oblast 630102, Russia
Perm, Permskiy Kray 614109, Russia
Saratov, Saratov Oblast 410012, Russia
Ulyanovsk, Ulyanovsk Oblast 432063, Russia
Yaroslavl, Yaroslavl Oblast 150040, Russia
Santiago de Compostela, La Coruna 15706, Spain
Madrid, Madrid, Comunidad de 28007, Spain
Kyiv, Kyivska Oblast 03038, Ukraine
Kyiv, Kyivska Oblast 03038, Ukraine
Kyiv, Kyivska Oblast 03057, Ukraine
Poltava, Poltava Oblast 36039, Ukraine
Vinnytsia, Vinnytsia Oblast 21001, Ukraine
Corby, Northamptonshire NN18 9EZ, United Kingdom
Orpington, Surrey BR5 3QG, United Kingdom
Northwood, Worcestershire HA6 2RN, United Kingdom